Claims for Patent: 9,238,039

Summary for Patent: 9,238,039

Title:	Pyrazolo[1,5-A]pyrimidines for antiviral treatment
Abstract:	The invention provides compounds of Formula I or Formula II: ##STR00001## or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
Inventor(s):	Babaoglu; Kerim (Pacifica, CA), Boojamra; Constantine G. (San Francisco, CA), Eisenberg; Eugene J. (San Carlos, CA), Hui; Hon Chung (San Mateo, CA), Mackman; Richard L. (Milbrae, CA), Parrish; Jay P. (Redwood City, CA), Sangi; Michael (Oakland, CA), Saunders; Oliver L. (San Mateo, CA), Siegel; Dustin (Foster City, CA), Sperandio; David (Palo Alto, CA), Yang; Hai (San Mateo, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	13/905,410
Patent Claims:	1. A compound of Formula I or Formula II: ##STR00776## or a pharmaceutically acceptable salt, thereof; wherein: A is --(C(R.sup.4).sub.2).sub.n-- wherein any one C(R.sup.4).sub.2 of said --(C(R.sup.4).sub.2).sub.n-- may be optionally replaced with --O--, --S--, --S(O).sub.p--, NH or NR.sup.a; n is 3, 4, 5 or 6; each p is 1 or 2; Ar is a monocyclic heterocyclyl group having 3 to 7 ring atoms or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, or a C.sub.6-C.sub.20 aryl group, wherein the monocyclic heterocyclyl group having 3 to 7 ring atoms, the bicyclic heterocyclyl group having 7 to 12 ring atoms, or the C.sub.6-C.sub.20 aryl group is optionally substituted with 1 to 5 R.sup.6; X is --C(R.sup.13)(R.sup.14)--, --N(CH.sub.2R.sup.14)-- or X is absent; Y is N or CR.sup.7; each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 or R.sup.8 is independently H, oxo, OR.sup.11, NR.sup.11R.sup.12, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)NR.sup.11R.sup.12, N.sub.3, CN, NO.sub.2, SR.sup.11, S(O).sub.pR.sup.a, NR.sup.11S(O).sub.pR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O).sub.p(OR.sup.11), --SO.sub.2NR.sup.11R.sup.12, --NR.sup.11S(O).sub.p(OR.sup.11), --NR.sup.11SO.sub.pNR.sup.11R.sup.12, NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; two R.sup.4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; four R.sup.4 on adjacent carbon atoms, when taken together, may form an optionally substituted C.sub.6 aryl ring; two R.sup.4 on the same carbon atom, when taken together, may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; two R.sup.6 on adjacent carbon atoms, when taken together, may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; any R.sup.6 adjacent to the obligate carbonyl group of said Ar, when taken together with R.sup.3, may form a bond or a--(C(R.sup.5).sub.2).sub.m-- group wherein m is 1 or 2; any R.sup.6 adjacent to the obligate carbonyl group of said Ar, when taken together with R.sup.2, may form a bond; each R.sup.a is independently (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, (C.sub.2-C.sub.8)alkenyl or (C.sub.2-C.sub.8)alkynyl of R.sup.a is optionally substituted with one or more OH, NH.sub.2, CO.sub.2H, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, and wherein any aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, monocyclic heterocyclyl group, or bicyclic heterocyclyl group of R.sup.a is optionally substituted with one or more substituents selected from OH, NH.sub.2, CO.sub.2H, (C.sub.1-C.sub.8)alkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, and a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; each R.sup.11 or R.sup.12 is independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, --C(.dbd.O)R.sup.a, --S(O).sub.pR.sup.a, aryl(C.sub.1-C.sub.8)alkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; or R.sup.11 and R.sup.12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with --O--, --S--, --S(O).sub.p--, --NH--, --NR.sup.a--or --C(O)--; R.sup.13 is H or (C.sub.1-C.sub.8)alkyl; R.sup.14 is H, (C.sub.1-C.sub.8)alkyl, NR.sup.11R.sup.12, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.12, NR.sup.11S(O).sub.pR.sup.a, --NR.sup.11S(O).sub.p(OR.sup.11) or NR.sup.11SO.sub.pNR.sup.11R.sup.12; and wherein each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, monocyclic heterocyclyl group having 3 to 7 ring atoms, bicyclic heterocyclyl group having 7 to 12 ring atoms, (C.sub.3-C.sub.7)cycloalkyl or (C.sub.4-C.sub.8)carbocyclylalkyl of each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.11 or R.sup.12 is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 2. The compound of claim 1 which is a compound of Formula I. 3. The compound of claim 1 wherein each R.sup.3 is H. 4. The compound of claim 1 which is a compound of Formula VII or a compound of Formula VIII: ##STR00777## or a pharmaceutically acceptable salt or ester, thereof. 5. The compound of claim 4 which is a compound of Formula VII. 6. The compound of claim 1 wherein R.sup.2 is H. 7. The compound of claim 1 wherein R.sup.7 is H, halogen or (C.sub.1-C.sub.8)alkyl. 8. The compound of claim 1 wherein n is 3 or 4. 9. The compound of claim 1 wherein each R.sup.4 is independently H or optionally substituted (C.sub.1-C.sub.8)alkyl, or four R.sup.4 on adjacent carbon atoms, when taken together, may form an optionally substituted C.sub.6 aryl ring. 10. The compound of claim 1 wherein A is --(CH.sub.2).sub.3--, --(CH.sub.2).sub.4--, --CH.sub.2--O--CH.sub.2--, --CH.sub.2--CH(CH.sub.3)--CH.sub.2--, --CH.sub.2--CH(CF.sub.3)--CH.sub.2--, --CH.sub.2--CH.sub.2--CH(CH.sub.3)-- or the structure: ##STR00778## 11. The compound of claim 1 wherein A is --(CH.sub.2).sub.3--. 12. The compound of claim 1 wherein X is --CR.sup.13(NR.sup.11C(O)OR.sup.11)--, --CR.sup.13(NR.sup.11R.sup.12)--, --CR.sup.13(NR.sup.11S(O).sub.pR.sup.a)-- or X is absent. 13. The compound of claim 1 wherein X is absent. 14. The compound of claim 1 wherein R.sup.1 is H, OR.sup.11, NR.sup.11R.sup.12, CN, (C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any (C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, monocyclic heterocyclyl group having 3 to 7 ring atoms, or bicyclic heterocyclyl group having 7 to 12 ring atoms of R.sup.1 is optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 15. The compound of claim 1 wherein R.sup.1 is H, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any monocyclic heterocyclyl group having 3 to 7 ring atoms or bicyclic heterocyclyl group having 7 to 12 ring atoms of R.sup.1 is optionally substituted with or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 16. The compound of claim 1 wherein R.sup.1 is selected from: ##STR00779## ##STR00780## 17. The compound of claim 1 wherein R.sup.1 is H or: ##STR00781## 18. The compound of claim 1 wherein Ar is a C.sub.6-C.sub.20 aryl group, wherein the C.sub.6-C.sub.20 aryl group is optionally substituted with 1 to 5 R.sup.6. 19. The compound of claim 1 wherein Ar is phenyl optionally substituted with 1 to 5 R.sup.6. 20. The compound of claim 1 wherein each R.sup.6 is independently selected from OR.sup.11, NR.sup.11R.sup.12, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11, CN, NR.sup.11S(O).sub.pR.sup.a, --C(.dbd.O)NR.sup.11R.sup.12, --NR.sup.11SO.sub.pNR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkynyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, and a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkynyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, monocyclic heterocyclyl group having 3 to 7 ring atoms, or bicyclic heterocyclyl group having 7 to 12 ring atoms of R.sup.6 is optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 21. The compound of claim 1 wherein each R.sup.6 is independently selected from NR.sup.11S(O).sub.pR.sup.a, NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)R.sup.11, (C.sub.1-C.sub.8)alkyl and halogen. 22. The compound of claim 1 wherein Ar is: ##STR00782## ##STR00783## ##STR00784## ##STR00785## ##STR00786## ##STR00787## ##STR00788## ##STR00789## ##STR00790## ##STR00791## ##STR00792## 23. The compound of claim 1 wherein Ar is: ##STR00793## 24. The compound of claim 1 wherein R.sup.8 is H, NR.sup.11R.sup.12, NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkynyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkynyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, monocyclic heterocyclyl group having 3 to 7 ring atoms, or bicyclic heterocyclyl group having 7 to 12 ring atoms of R.sup.8 is optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 25. The compound of claim 1 wherein R.sup.8 is a monocyclic heterocyclyl group having 3 to 7 ring atoms or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein monocyclic heterocyclyl group having 3 to 7 ring atoms or the bicyclic heterocyclyl group having 7 to 12 ring atoms is optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 26. The compound of claim 1 wherein R.sup.8 is pyrrolidinyl or azetidinyl, wherein pyrrolidinyl or azetidinyl is optionally substituted with one or more hydroxy, NH.sub.2, CN or --OP(O)(OH).sub.2. 27. The compound of claim 1 wherein R.sup.8 is: ##STR00794## ##STR00795## ##STR00796## ##STR00797## 28. The compound of claim 1 wherein R.sup.8 is: ##STR00798## 29. The compound according to claim 1 selected from the group consisting of: ##STR00799## ##STR00800## ##STR00801## ##STR00802## ##STR00803## ##STR00804## ##STR00805## ##STR00806## ##STR00807## ##STR00808## ##STR00809## ##STR00810## ##STR00811## ##STR00812## ##STR00813## ##STR00814## ##STR00815## ##STR00816## ##STR00817## ##STR00818## ##STR00819## ##STR00820## ##STR00821## ##STR00822## ##STR00823## ##STR00824## ##STR00825## ##STR00826## ##STR00827## ##STR00828## ##STR00829## ##STR00830## ##STR00831## ##STR00832## ##STR00833## ##STR00834## ##STR00835## ##STR00836## ##STR00837## ##STR00838## ##STR00839## ##STR00840## ##STR00841## ##STR00842## ##STR00843## ##STR00844## ##STR00845## ##STR00846## ##STR00847## ##STR00848## ##STR00849## ##STR00850## ##STR00851## ##STR00852## ##STR00853## ##STR00854## ##STR00855## ##STR00856## ##STR00857## ##STR00858## ##STR00859## ##STR00860## ##STR00861## ##STR00862## ##STR00863## ##STR00864## ##STR00865## ##STR00866## ##STR00867## ##STR00868## ##STR00869## ##STR00870## ##STR00871## ##STR00872## ##STR00873## ##STR00874## ##STR00875## ##STR00876## ##STR00877## ##STR00878## ##STR00879## ##STR00880## ##STR00881## and pharmaceutically acceptable salts thereof. 30. The compound according to claim 1 selected from the group consisting of: ##STR00882## ##STR00883## and pharmaceutically acceptable salts thereof. 31. A compound according to claim 1 selected from the group of: ##STR00884## ##STR00885## ##STR00886## ##STR00887## ##STR00888## ##STR00889## ##STR00890## ##STR00891## ##STR00892## ##STR00893## ##STR00894## ##STR00895## ##STR00896## ##STR00897## ##STR00898## ##STR00899## ##STR00900## ##STR00901## ##STR00902## ##STR00903## ##STR00904## ##STR00905## ##STR00906## ##STR00907## ##STR00908## ##STR00909## ##STR00910## ##STR00911## ##STR00912## ##STR00913## ##STR00914## ##STR00915## ##STR00916## ##STR00917## ##STR00918## ##STR00919## ##STR00920## ##STR00921## ##STR00922## ##STR00923## ##STR00924## ##STR00925## ##STR00926## ##STR00927## ##STR00928## ##STR00929## ##STR00930## and pharmaceutically acceptable salts thereof. 32. A pharmaceutical composition comprising a compound of Formula IX: ##STR00931## or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; wherein: A is --(C(R.sup.4).sub.2).sub.n-- wherein any one C(R.sup.4).sub.2 of said --(C(R.sup.4).sub.2).sub.n-- may be optionally replaced with --O--, --S--, S(O).sub.p--, NH or NR.sup.a; n is 3, 4, 5 or 6; each p is 1 or 2; Ar is a monocyclic heterocyclyl group having 3 to 7 ring atoms or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, or a C.sub.6-C.sub.20 aryl group, wherein the monocyclic heterocyclyl group having 3 to 7 ring atoms, the bicyclic heterocyclyl group having 7 to 12 ring atoms, or the C.sub.6-C.sub.20 aryl group is optionally substituted with 1 to 5 R.sup.6; X is --(CR.sup.13R.sup.14)--, --N(CH.sub.2R.sup.14)-- or X is absent; Y is N or CR.sup.7; each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 or R.sup.8 is independently H, oxo, OR.sup.11, NR.sup.11R.sup.12NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.12, N.sub.3, CN, NO.sub.2, SR.sup.11, S(O).sub.pR.sup.a, NR.sup.11S(O).sub.pR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O).sub.p(OR.sup.11), --SO.sub.2NR.sup.11R.sup.12, --NR.sup.11S(O).sub.p(OR.sup.11), --NR.sup.11SO.sub.pNR.sup.11R.sup.12, NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; two R.sup.4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; four R.sup.4 on adjacent carbon atoms, when taken together, may form an optionally substituted C.sub.6 aryl ring; two R.sup.4 on the same carbon atom, when taken together, may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; two R.sup.6 on adjacent carbon atoms, when taken together, may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; any R.sup.6 adjacent to the obligate carbonyl group of said Ar, when taken together with R.sup.3, may form a bond or a --(C(R.sup.5).sub.2).sub.m-- group wherein m is 1 or 2; any R.sup.6 adjacent to the obligate carbonyl group of said Ar, when taken together with R.sup.2, may form a bond; each R.sup.a is independently (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, (C.sub.2-C.sub.8)alkenyl or (C.sub.2-C.sub.8)alkynyl of R.sup.a is optionally substituted with one or more substitutents selected from OH, NH.sub.2, CO.sub.2H, a monocyclic heterocyclyl group having 3 to 7 ring atoms, and a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, and wherein any aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms of R.sup.a is optionally substituted with one or more substituents selected from OH, NH.sub.2, CO.sub.2H, (C.sub.1-C.sub.8)alkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, and a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; each R.sup.11 or R.sup.12 is independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, --C(.dbd.O)R.sup.a, --S(O).sub.pR.sup.a, aryl(C.sub.1-C.sub.8)alkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; or R.sup.11 and R.sup.12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with --O--, --S--, --S(O).sub.p--, --NH--, --NR.sup.a-- or --C(O)--; R.sup.13 is H or (C.sub.1-C.sub.8)alkyl; R.sup.14 is H, (C.sub.1-C.sub.8)alkyl, NR.sup.11R.sup.12, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.12, NR.sup.11S(O).sub.pR.sup.a, --NR.sup.11S(O).sub.p(OR.sup.11) or NR.sup.11SO.sub.pNR.sup.11R.sup.12; and wherein each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, monocyclic heterocyclyl group having 3 to 7 ring atoms, or bicyclic heterocyclyl group having 7 to 12 ring atoms of each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.11 or R.sup.12 is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 33. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 34. The pharmaceutical composition of claim 32 or claim 33 further comprising at least one other therapeutic agent selected from ribavirin, palivizumab, motavizumab, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 or ALX-0171 mixtures thereof. 35. A method of treating a Pneumovirinae virus infection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of Formula IX: ##STR00932## or a pharmaceutically acceptable salt thereof, wherein: A is --(C(R.sup.4).sub.2).sub.n-- wherein any one C(R.sup.4).sub.2 of said --(C(R.sup.4).sub.2).sub.n-- may be optionally replaced with --O--, --S--, S(O)--, NH or NR.sup.a; n is 3, 4, 5 or 6; each p is 1 or 2; Ar is a monocyclic heterocyclyl group having 3 to 7 ring atoms or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, or a C.sub.6-C.sub.20 aryl group, wherein the monocyclic heterocyclyl group having 3 to 7 ring atoms, the bicyclic heterocyclyl group having 7 to 12 ring atoms, or the C.sub.6-C.sub.20 aryl group is optionally substituted with 1 to 5 R.sup.6; X is --(CR.sup.13R.sup.14)--, --N(CH.sub.2R.sup.14)-- or X is absent; Y is N or CR.sup.7; each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 or R.sup.8 is independently H, oxo, OR.sup.11, NR.sup.11R.sup.12, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.12, N.sub.3, CN, NO.sub.2, SR.sup.11, S(O).sub.pR.sup.a, NR.sup.11S(O).sub.pR.sup.a, --C(.dbd.O)R.sup.11, --C(.dbd.O)OR.sup.11, --C(.dbd.O)NR.sup.11R.sup.12, --C(.dbd.O)SR.sup.11, --S(O).sub.p(OR.sup.11), --SO.sub.2NR.sup.11R.sup.12, --NR.sup.11S(O).sub.p(OR.sup.11), --NR.sup.11SO.sub.pNR.sup.11R.sup.12, NR.sup.11C(.dbd.NR.sup.11)NR.sup.11R.sup.12, halogen, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; two R.sup.4 on adjacent carbon atoms, when taken together, may form a double bond between the two carbons to which they are attached or may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.P--, --NH-- or --NR.sup.a--; four R.sup.4 on adjacent carbon atoms, when taken together, may form an optionally substituted C.sub.6 aryl ring; two R.sup.4 on the same carbon atom, when taken together, may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; two R.sup.6 on adjacent carbon atoms, when taken together, may form a (C.sub.3-C.sub.7)cycloalkyl ring wherein one carbon atom of said (C.sub.3-C.sub.7)cycloalkyl ring may be optionally replaced by --O--, --S--, --S(O).sub.p--, --NH-- or --NR.sup.a--; any R.sup.6 adjacent to the obligate carbonyl group of said Ar, when taken together with R.sup.3, may form a bond or a --(C(R.sup.5).sub.2).sub.m-- group wherein m is 1 or 2; any R.sup.6 adjacent to the obligate carbonyl group of said Ar, when taken together with R.sup.2, may form a bond; each R.sup.a is independently (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, wherein any (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, (C.sub.2-C.sub.8)alkenyl or (C.sub.2-C.sub.8)alkynyl of R.sup.a is optionally substituted with one or more substituents selected from OH, NH.sub.2, CO.sub.2H, a monocyclic heterocyclyl group having 3 to 7 ring atoms, and a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S, and wherein any aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, monocyclic heterocyclyl group having 3 to 7 ring atoms, bicyclic heterocyclyl group having 7 to 12 ring atoms, (C.sub.3-C.sub.7)cycloalkyl or (C.sub.4-C.sub.8)carbocyclylalkyl of R.sup.a is optionally substituted with one or more OH, NH.sub.2, CO.sub.2H, (C.sub.1-C.sub.8)alkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; each R.sup.11 or R.sup.12 is independently H, (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, (C.sub.3-C.sub.7)cycloalkyl, (C.sub.4-C.sub.8)carbocyclylalkyl, --C(.dbd.O)R.sup.a, --S(O).sub.pR.sup.a, aryl(C.sub.1-C.sub.8)alkyl, a monocyclic heterocyclyl group having 3 to 7 ring atoms, or a bicyclic heterocyclyl group having 7 to 12 ring atoms, the monocyclic and bicyclic heterocyclyl groups having 1, 2, 3, or 4 hetero ring atoms selected from O, N, or S; or R.sup.11 and R.sup.12 taken together with a nitrogen to which they are both attached form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with --O--, --S--, --S(O).sub.p--, --NH--, --NR.sup.a-- or --C(O)--; R.sup.13 is H or (C.sub.1-C.sub.8)alkyl; R.sup.14 is H, (C.sub.1-C.sub.8)alkyl, NR.sup.11R.sup.12, NR.sup.11C(O)R.sup.11, NR.sup.11C(O)OR.sup.11, NR.sup.11C(O)NR.sup.11R.sup.12, NR.sup.11S(O).sub.pR.sup.a, --NR.sup.11S(O).sub.p(OR.sup.11) or NR.sup.11SO.sub.pNR.sup.11R.sup.12; and wherein each (C.sub.1-C.sub.8)alkyl, (C.sub.2-C.sub.8)alkenyl, (C.sub.2-C.sub.8)alkynyl, aryl(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.20 aryl, monocyclic heterocyclyl group, bicyclic heterocyclyl group, (C.sub.3-C.sub.7)cycloalkyl or (C.sub.4-C.sub.8)carbocyclylalkyl of each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.11 or R.sup.12 is, independently, optionally substituted with one or more oxo, halogen, hydroxy, NH.sub.2, CN, N.sub.3, N(R.sup.a).sub.2, NHR.sup.a, SH, SR.sup.a, S(O).sub.pR.sup.a, OR.sup.a, (C.sub.1-C.sub.8)alkyl, (C.sub.1-C.sub.8)haloalkyl, --C(O)R.sup.a, --C(O)H, --C(.dbd.O)OR.sup.a, --C(.dbd.O)OH, --C(.dbd.O)N(R.sup.a).sub.2, --C(.dbd.O)NHR.sup.a, --C(.dbd.O)NH.sub.2, NHS(O).sub.pR.sup.a, NR.sup.aS(O).sub.pR.sup.a, NHC(O)R.sup.a, NR.sup.aC(O)R.sup.a, NHC(O)OR.sup.a, NR.sup.aC(O)OR.sup.a, NR.sup.aC(O)NHR.sup.a, NR.sup.aC(O)N(R.sup.a).sub.2, NR.sup.aC(O)NH.sub.2, NHC(O)NHR.sup.a, NHC(O)N(R.sup.a).sub.2, NHC(O)NH.sub.2, .dbd.NH, .dbd.NOH, .dbd.NOR.sup.a, NR.sup.aS(O).sub.pNHR.sup.a, NR.sup.aS(O).sub.pN(R.sup.a).sub.2, NR.sup.aS(O).sub.pNH.sub.2, NHS(O).sub.pNHR.sup.a, NHS(O).sub.pN(R.sup.a).sub.2, NHS(O).sub.pNH.sub.2, --OC(.dbd.O)R.sup.a, --OP(O)(OH).sub.2 or R.sup.a. 36. A method of treating a Pneumovirinae virus infection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 37. The method of claim 35 or 36 wherein the Pneumovirinae virus infection is caused by a respiratory syncytial virus. 38. The method of claim 35 or 36 further comprising administering a therapeutically effective amount of at least one other therapeutic agent or composition thereof selected from the group consisting of ribavirin, palivizumab, motavizumab, RSV-IGIV MEDI-557, A-60444, MDT-637, BMS-433771, ALN-RSV0 and ALX-0171 or mixtures thereof.

Details for Patent 9,238,039

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2030-06-24
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2030-06-24
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2030-06-24
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2030-06-24